Dados do Trabalho

Título

EVALUATION OF THE EFFICACY OF OVARIAN FUNCTION SUPPRESSION WITH 3-MONTHLY GONADOTROPIN-RELEASING HORMONE ANALOGUE REGIMEN IN PREMENOPAUSAL BREAST CANCER

Introdução

A previous phase 3 trial demonstrated that 3-monthly goserelin 10.8 mg was non-inferior to monthly goserelin 3.6 mg for progression free survival (PFS) rate at 24 weeks, in premenopausal women with early estrogen receptor (ER)-positive breast cancer, who received concomitant tamoxifen 20 mg daily. However, the efficacy of 3-montlhy goserelin plus aromatase inhibitors (AI) has not yet been determined.

Objetivo

This retrospective cohort study aimed to evaluate the efficacy of ovarian function suppression (OFS) with 3-monthly goserelin compared to monthly goserelin, both associated with AI, in premenopausal patients with ER-positive breast cancer.

Método

Premenopausal patients who underwent OFS with 3-monthly goserelin 10.8 mg or monthly goserelin 3.6 mg subcutaneously, in association with AI, were evaluated. Patient characteristics, such as age, body mass index (BMI) and previous chemotherapy, as well as estradiol (E2) levels were collected and compared retrospectively. The analysis of E2 measurements was divided into periods (months): less than 3, from 3 to 6, 6 to 12, 12 to 18, 18 to 24 and greater than 24 months. The proportion of patients with E2 levels greater than 2.72 pg/mL, measured by gas chromatography tandem mass spectrometry, was evaluated at each time period. Patients who had at least an E2 level above the aforementioned limit were considered to have failed OFS.

Resultado

A total of 53 patients met the inclusion criteria, of which 24 (45.2%) received monthly goserelin 3.6 mg and 29 (54.7%) received 3-montlhy goserelin 10.8 mg. Patient characteristics were well balanced between the groups. Regarding estradiol analysis, 9 (17%) patients had at least one measurement greater than 2.72 pg/ml, 7 (77.8%) in the monthly group and 2 (22.2%) in the 3-montlhy group. In the monthly group, we observed higher percentages of patients with E2 measurements greater than 2.72 pg/ml, in the periods from 0 to 3, 3 to 6, 6 to 12, 12 to 18 and 18 to 24 months: 33.3%, 30%, 15.4 %, 14.3%, 50%, respectively. After 24 months, we didn´t identify measurements above the mentioned limit. In relation to the 3-montlhy group, in periods of less than 3 months and from 3 to 6 months, 7.7% and 11.1% of patients had E2 levels above 2.72 pg/ml, respectively. After 6 months, no measurements above the referred limit were observed.

Conclusão

This study demonstrated that OFS with 3-montlhy goserelin had at least a similar efficacy to monthly goserelin, when associated with AI, promoting greater convenience for patients.

Palavras-chave

Breast cancer, ovarian function suppression, goserelin